Article

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancer

2019-11-10

Abstract excerpt

<h4>Background</h4> Little is known about mechanisms of resistance to PARP inhibitors and platinum chemotherapy in patients with metastatic breast cancer and BRCA1 /2 mutations. Further investigation of resistance in clinical cohorts may point to strategies to prevent or overcome treatment failure. <h4>Patients and Methods</h4> We obtained tumor biopsies from metastatic breast cancer patients with BRCA1/2 def...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9c6ab582-deda-5d5e-a53d-c7f9f06c4c05
DOI: 10.1101/832717

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancerDOI 10.1101/832717Read

A meta-analysis of clinical cases of reversion mutations in <i>BRCA</i> genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceSemantic proximity Read

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.Semantic proximity Read

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.Semantic proximity Read

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.Semantic proximity Read

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.Semantic proximity Read

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerSemantic proximity Read

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.Semantic proximity Read

Reversion mutations define minimal <i>BRCA1/2</i> requirements for therapy resistanceSemantic proximity Read

Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.Semantic proximity Read

Decoding the <i>BRCA2</i> reversion principles underlying PARP inhibitor resistanceSemantic proximity Read

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.Semantic proximity Read

Landscape of reversion alterations in homologous recombination genes reveals evolutionary constraintsSemantic proximity Read